Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference
Kairos Pharma Ltd. (NYSE American: KAPA) will present its advancements in cancer therapeutics at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its potential to address drug resistance in cancer treatments.
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics, is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference. The event, taking place from September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City, will feature Kairos Pharma in one-on-one meetings and a virtual presentation accessible via kairospharma.com.
The company's lead candidate, ENV105, targets CD105, a protein implicated in resistance to various cancer treatments. By focusing on CD105, ENV105 aims to reverse drug resistance, thereby enhancing the efficacy of standard therapies across multiple cancer types. Currently, ENV105 is undergoing Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer, addressing critical gaps in cancer treatment.
This participation underscores Kairos Pharma's commitment to advancing oncology therapeutics and its potential to make significant strides in overcoming drug resistance and immune suppression in cancer. For further details on Kairos Pharma's innovative approaches to cancer treatment, visit kairospharma.com.